Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D
Nature (2004)
Thymosin β4 promoted myocyte migration and survival through an integrin-linked-kinase / Akt pathway and improved cardiac function in mice after coronary artery ligation — the mechanistic foundation for everything that followed in the cardiac-repair literature.
This 2004 *Nature* paper from the Srivastava laboratory is the most-cited primary source for thymosin β4's cardiac-repair mechanism and a foundational anchor for the broader case that the molecule is more than a passive G-actin sequester. The investigators showed that thymosin β4 promotes myocardial and endothelial cell migration in embryonic mouse hearts and retains that activity in postnatal cardiomyocytes — meaning the developmental migration program is reactivatable in adult cardiac tissue. They then identified a downstream pathway: thymosin β4 forms a complex with PINCH and integrin-linked kinase (ILK), which activates the pro-survival kinase Akt. In a coronary artery ligation model in mice, thymosin β4 administration upregulated ILK and Akt activity in the heart, enhanced cardiomyocyte survival in the early post-infarct window, and improved cardiac function on functional assessment. The paper concludes that the thymosin β4 pathway represents a candidate therapeutic target for acute myocardial damage, a framing that subsequently drove RegeneRx's clinical-development program for the molecule in cardiac and other repair indications.
This is a rodent mechanism paper, not a human trial. The infarct model uses ligation in mice; translation to human acute coronary syndromes is an inference, not a demonstrated equivalence. The functional improvements reported are real but were measured on relatively small cohorts and short follow-up windows typical of a single-paper mechanistic study. Subsequent attempts to replicate or extend the cardiac-reprogramming claim — particularly the "epicardial cells reprogram into cardiomyocytes" framing some early commentary attached to thymosin β4 — have produced mixed results, with at least one published replication study (Zhou et al., Circulation Research 2013) failing to show epicardial-to-cardiomyocyte conversion after MI. The actin-sequestration and migration mechanisms remain well-supported; the most ambitious cardiac-regeneration framing was always more contested than press coverage suggested.